BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OrthoMimetics Expands Board of Directors


7/1/2009 12:23:41 PM

Cambridge UK, 30 June 2009 Orthomimetics, the Cambridge-based developer of products for regenerative medicine, has appointed Patrick West, former Global Vice President of Sales and Marketing at Stryker Biotech, to its Board of Directors.

During an eight-year tenure as Global VP of Sales and Marketing for Stryker Biotech, Patrick was responsible for the development and management of a global sales force for Stryker’s first-in-class bone morphogenetic protein product. Prior to this appointment, he had been an award-winning sales representative for Stryker’s Endoscopy division, and held responsibility for the development and market expansion activities in the Instruments division. Subsequent to his experience with Stryker, Patrick founded and served as CEO of MaxTorque LLC, a company operating in the oil and gas space. Under Patrick’s guidance, MaxTorque achieved industry-leading revenue and profit growth that culminated in the recent acquisition of the company by a strategic partner.

Commenting on the appointment, Andrew Lynn, CEO of Orthomimetics said: “Patrick brings a unique combination of large orthopaedic company and successful entrepreneurial experience to the table. This is particularly important as we turn our focus to the controlled launch of our flagship product, Chondromimetic and consider global commercial opportunities. Patrick has already made a significant contribution to Orthomimetics through his work as a Senior Commercial Advisor and we are very pleased to deepen this relationship by welcoming him to the Board.”

With regulatory approval for Chondromimetic received for Europe in December 2008, a clinical development program already underway and negotiations for European distribution in progress, OM is now looking to build its commercial links with markets worldwide.

Orthomimetics Limited is a medical technology company specialising in the design, development and manufacture of regenerative medical implants and minimally invasive delivery systems for the treatment of sports injuries, trauma and other conditions that affect knees, ankles and other articular joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT Institute, the company is bringing to market a line of medical device products designed to improve the treatment outcome of first-line surgical procedures for the regenerative repair of articular cartilage, meniscus, ligament and tendon injuries using natural biomaterials. These products are engineered to be compatible with existing surgical techniques and to work in combination with emerging cell- and biologics-based products.

For further information on Orthomimetics please go to our website: www.orthomimetics.com or contact Katherine Webster: info@orthomimetics.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES